Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
8
×
life sciences
national blog main
new york top stories
national top stories
new york blog main
biotech
boston blog main
boston top stories
fda
indiana blog main
indiana top stories
national
san diego blog main
san diego top stories
san francisco top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
europe top stories
raleigh-durham blog main
raleigh-durham top stories
san francisco blog main
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
alnylam pharmaceuticals
cancer
europe blog main
gene therapy
new york
novartis
pfizer
roche
spark therapeutics
type 1 diabetes
What
drug
8
×
patients
8
×
fda
approved
medicine
new
bio
disease
friday
help
market
medicines
roundup
sets
therapy
type
acorda
advantages
ago
akcea
alnylam
amyloidosis
approval
aren’t
atrophy
attr
available
bar
battle
bid
biologic
boehringer
bottleneck
brings
cancer
clinical
cope
daily
debilitating
developers
Language
unset
Current search:
patients
×
drug
×
" clinical trials "
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Acorda Gets FDA Nod For New Parkinson’s Drug, But Rival Looms
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com
5 years ago
Fixing the Clinical Trial Bottleneck by Making Patients a Priority